JP2003238406A5 - - Google Patents

Download PDF

Info

Publication number
JP2003238406A5
JP2003238406A5 JP2002356114A JP2002356114A JP2003238406A5 JP 2003238406 A5 JP2003238406 A5 JP 2003238406A5 JP 2002356114 A JP2002356114 A JP 2002356114A JP 2002356114 A JP2002356114 A JP 2002356114A JP 2003238406 A5 JP2003238406 A5 JP 2003238406A5
Authority
JP
Japan
Prior art keywords
group
substituted
pharmaceutical composition
composition according
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002356114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003238406A (ja
JP5249484B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2002356114A priority Critical patent/JP5249484B2/ja
Priority claimed from JP2002356114A external-priority patent/JP5249484B2/ja
Publication of JP2003238406A publication Critical patent/JP2003238406A/ja
Publication of JP2003238406A5 publication Critical patent/JP2003238406A5/ja
Application granted granted Critical
Publication of JP5249484B2 publication Critical patent/JP5249484B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002356114A 2001-12-11 2002-12-09 医薬組成物 Expired - Fee Related JP5249484B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002356114A JP5249484B2 (ja) 2001-12-11 2002-12-09 医薬組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-376954 2001-12-11
JP2001376954 2001-12-11
JP2001376954 2001-12-11
JP2002356114A JP5249484B2 (ja) 2001-12-11 2002-12-09 医薬組成物

Publications (3)

Publication Number Publication Date
JP2003238406A JP2003238406A (ja) 2003-08-27
JP2003238406A5 true JP2003238406A5 (enExample) 2006-03-30
JP5249484B2 JP5249484B2 (ja) 2013-07-31

Family

ID=27790693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002356114A Expired - Fee Related JP5249484B2 (ja) 2001-12-11 2002-12-09 医薬組成物

Country Status (1)

Country Link
JP (1) JP5249484B2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101068770B (zh) 2004-09-28 2012-01-04 三共株式会社 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
JP4789180B2 (ja) * 2004-09-28 2011-10-12 第一三共株式会社 ６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
WO2007091622A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
TW200838512A (en) * 2007-02-08 2008-10-01 Daiichi Sankyo Co Ltd Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
JPWO2010013768A1 (ja) * 2008-07-31 2012-01-12 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
US20110160462A1 (en) 2008-07-31 2011-06-30 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282548B6 (cs) * 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
AU5664294A (en) * 1993-01-11 1995-02-28 Ligand Pharmaceuticals, Inc. Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
MX9306629A (es) * 1993-01-11 1994-07-29 Ligand Pharm Inc Compuestos que tienen actividad selectiva para receptores retinoide x, medios para modulacion de procesos mediados pr receptores de retinoide x.
BR9610875A (pt) * 1995-10-06 1999-07-13 Ligand Pharm Inc Modulares rxr seletivos - dimeros e processos para seu uso
EP0948324B1 (en) * 1996-12-11 2003-11-12 Dana-Farber Cancer Institute, Inc. Methods and pharmaceutical compositions for inhibiting tumour cell growth comprising a ppar-gamma agonist and a map kinase inhibitor
AU5811298A (en) * 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
PL334840A1 (en) * 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation
JP3488099B2 (ja) * 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
KR20020010581A (ko) * 1999-03-11 2002-02-04 사단호진 산교 소죠켄큐쇼 핵수용체 ｐｐａｒ의 신규한 리간드
JP4169450B2 (ja) * 1999-04-07 2008-10-22 第一三共株式会社 インスリン抵抗性改善剤
JP4197387B2 (ja) * 1999-04-07 2008-12-17 第一三共株式会社 アミン誘導体化合物
CA2369910A1 (en) * 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases

Similar Documents

Publication Publication Date Title
JP2005501120A5 (enExample)
JP2010510999A5 (enExample)
JP2006507326A5 (enExample)
ZA200500253B (en) Ketones
JP2013505969A5 (enExample)
JP2006517572A5 (enExample)
JPH10195063A5 (enExample)
EP2379537A2 (en) Organic compounds
ME02331B (me) Derivati benzotiazola kao agensi protiv kancera
JP2005519908A5 (enExample)
JP2002030084A5 (enExample)
CA2529686A1 (en) 2-acylaminothiazole derivative or salt thereof
JP2011506501A5 (enExample)
JP2005505583A5 (enExample)
JP2014533735A (ja) 外寄生生物を防除するためのアリール誘導体の使用
JP2005503435A5 (enExample)
JP2005535594A5 (enExample)
JP2003238406A5 (enExample)
JP2004521150A5 (enExample)
JP2009501745A5 (enExample)
WO2012040170A2 (en) Compositions and methods for treating tuberculosis
JP2005522492A5 (enExample)
JP2007505105A5 (enExample)
JP2011524362A5 (enExample)
ES2715394T3 (es) Nuevo antifúngico derivado de oxodihidropiridinacarbohidrazida